Poly(l-threonine-<i>co</i>-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.
Biomacromolecules · 2024
Last updated 2026-05-28A new gel-like material (PTTs) was developed to slowly release the diabetes drug lixisenatide. When tested, 77% of the lixisenatide dose was released over 14 days, and blood sugar control lasted 7–10 days in diabetic rats. The gel worked by using electrical charge to reduce the initial rapid release of the drug.
AI summary of the abstract below.
| Journal | Biomacromolecules, 2024 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.74 |
| NIH percentile | 41 |
| Molecules | lixisenatide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Negatively charged poly(l-Thr--l-Thr succinate) (PTTs) was developed as a new thermogel. Aqueous PTT solutions underwent thermogelation over a concentration range of 6.0-8.3 wt %. Dynamic light scattering, FTIR, H NMR, and COSY spectra revealed the partial strengthening of the β-sheet conformation and the dehydration of PTTs during the transition. Extendin-4 was released from the PTTs thermogel with a large initial burst release, whereas positively charged lixisenatide significantly reduced its initial burst release to 25%, and up to 77% of the dose was released from the gel over 14 days. In vivo study revealed a high plasma concentration of lixisenatide over 5 days and hypoglycemic efficacy was observed for type II diabetic rats over 7-10 days. The biocompatible PTTs were degraded by subcutaneous enzymes. This study thus demonstrates an effective strategy for reducing the initial burst release of protein drugs from thermogels with the introduction of electrostatic interactions between the drug and the thermogel.
Verbatim abstract via PubMed 38949062 ↗
Related research
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
- Trial of Lixisenatide in Early Parkinson's Disease.
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.